Article

Discovery of a new signaling pathway that regulates IOP

Researchers have discovered elevated expression of sFRP1, a WNT signaling inhibitor, in glaucomatous trabecular meshwork (TM) cells. They also observed that the TM has a functional signaling pathway in which elevated sFRP1 decreased outflow facility, according to one researcher.

Researchers have discovered elevated expression of sFRP1 (secreted frizzled related protein), a WNT signaling inhibitor, in glaucomatous trabecular meshwork (TM) cells. They also observed that the TM has a functional signaling pathway in which elevated sFRP1 decreased outflow facility, according to one researcher.

"This validates a new signaling pathway in the TM that regulates IOP," said Abbot F. Clark, senior director of glaucoma research, Alcon Laboratories, Fort Worth, TX.

Gene expression was compared using total RNA isolated from 6 normal and 6 glaucomatous cultured TM cells. After differential gene expression was confirmed, the effect of altered expression on IOP was determined using perfusion cultured human anterior segments and viral expression vector transduction of mouse eyes.

A four- to five-fold increase in the expression of sFRP1 was found in the glaucomatous TM cells. This was confirmed at the protein level.

"We are hypothesizing that sFRP1 blocks WNT signaling, and that leads to an increase in IOP," Dr. Clark said.

An apparent correlation also was found between sFRP1 expression and the signaling mediator beta-catenin. High levels of sFRP1 were associated with low levels of beta-catenin, and the inverse was also observed.

Looking for the effects of this expression, Dr. Clark and colleagues found a statistically significant decrease in outflow facility in perfusion cultured human eyes. Those eyes that received sFRP1 also had lower levels of beta-catenin.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.